{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:23:46Z","timestamp":1794471826953,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8062","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,5,8]]},"DOI":"10.1038\/s41586-025-08717-5","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:14:19Z","timestamp":1742386459000},"page":"503-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Oncolytic virus VG161 in refractory hepatocellular carcinoma"],"prefix":"10.1038","volume":"641","author":[{"given":"Yinan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2934-0880","authenticated-orcid":false,"given":"Xueli","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3817-9117","authenticated-orcid":false,"given":"Guoming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guyue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sida","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longshen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeting","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Rahimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9396-1502","authenticated-orcid":false,"given":"Manu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanal","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-3353","authenticated-orcid":false,"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"8717_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345\u20131362 (2022).","journal-title":"Lancet"},{"key":"8717_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA 73, 17\u201348 (2023).","journal-title":"CA"},{"key":"8717_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin, D., Shen, Y. & Liang, T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct. Target. Ther. 8, 156 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"8717_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/biomedicines8110484","volume":"8","author":"DV Chouljenko","year":"2020","unstructured":"Chouljenko, D. V. et al. Induction of durable antitumor response by a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Biomedicines 8, 484 (2020).","journal-title":"Biomedicines"},{"key":"8717_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"8717_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"8717_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54\u201363 (2018).","journal-title":"N. Engl. J. Med."},{"key":"8717_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56\u201366 (2017).","journal-title":"Lancet"},{"key":"8717_CR9","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","volume":"19","author":"R Lencioni","year":"2013","unstructured":"Lencioni, R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin. Cancer Res. 19, 1312\u20131314 (2013).","journal-title":"Clin. Cancer Res."},{"key":"8717_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ijcp.12352","volume":"68","author":"R Lencioni","year":"2014","unstructured":"Lencioni, R. et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int. J. Clin. Pract. 68, 609\u2013617 (2014).","journal-title":"Int. J. Clin. Pract."},{"key":"8717_CR11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"8717_CR12","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"8717_CR13","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","volume":"39","author":"RK Kelley","year":"2021","unstructured":"Kelley, R. K. et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study. J. Clin. Oncol. 39, 2991\u20133001 (2021).","journal-title":"J. Clin. Oncol."},{"key":"8717_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"J Heo","year":"2013","unstructured":"Heo, J. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329\u2013336 (2013).","journal-title":"Nat. Med."},{"key":"8717_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1615817","volume":"8","author":"M Moehler","year":"2019","unstructured":"Moehler, M. et al. Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter phase IIb trial (TRAVERSE). Oncoimmunology 8, 1615817 (2019).","journal-title":"Oncoimmunology"},{"key":"8717_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","volume":"17","author":"HL Kaufman","year":"2010","unstructured":"Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718\u2013730 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"8717_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","volume":"14","author":"JH Kim","year":"2006","unstructured":"Kim, J. H. et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14, 361\u2013370 (2006).","journal-title":"Mol. Ther."},{"key":"8717_CR18","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539\u20133543 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8717_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.imbio.2017.07.001","volume":"223","author":"RSE Tamadaho","year":"2018","unstructured":"Tamadaho, R. S. E., Hoerauf, A. & Layland, L. E. Immunomodulatory effects of myeloid-derived suppressor cells in diseases: role in cancer and infections. Immunobiology 223, 432\u2013442 (2018).","journal-title":"Immunobiology"},{"key":"8717_CR20","doi-asserted-by":"publisher","first-page":"e28108","DOI":"10.1002\/jmv.28108","volume":"95","author":"Y Shen","year":"2022","unstructured":"Shen, Y. et al. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. J. Med. Virol. 95, e28108 (2022).","journal-title":"J. Med. Virol."},{"key":"8717_CR21","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo, T. et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630\u20131639 (2022).","journal-title":"Nat. Med."},{"key":"8717_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52\u201360 (2010).","journal-title":"Semin. Liver Dis."},{"key":"8717_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet, J. M. & Lencioni, R. mRECIST for HCC: performance and novel refinements. J. Hepatol. 72, 288\u2013306 (2020).","journal-title":"J. Hepatol."},{"key":"8717_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2015.06.009","volume":"28","author":"R Arulanandam","year":"2015","unstructured":"Arulanandam, R. et al. VEGF-mediated induction of PRD1-BF1\/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell 28, 210\u2013224 (2015).","journal-title":"Cancer Cell"},{"key":"8717_CR25","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/mt.2008.112","volume":"16","author":"K Kurozumi","year":"2008","unstructured":"Kurozumi, K. et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol. Ther. 16, 1382\u20131391 (2008).","journal-title":"Mol. Ther."},{"key":"8717_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38, 193\u2013202 (2020).","journal-title":"J. Clin. Oncol."},{"key":"8717_CR27","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1634\/theoncologist.2020-0143","volume":"25","author":"ZZ Lin","year":"2020","unstructured":"Lin, Z. Z. et al. A multicenter phase II study of second-line axitinib for patients with advanced hepatocellular carcinoma failing first-line sorafenib monotherapy. Oncologist 25, e1280\u2013e1285 (2020).","journal-title":"Oncologist"},{"key":"8717_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","volume":"6","author":"S Qin","year":"2021","unstructured":"Qin, S. et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol. Hepatol. 6, 559\u2013568 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"8717_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin, S. et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 21, 571\u2013580 (2020).","journal-title":"Lancet Oncol."},{"key":"8717_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1729300","volume":"9","author":"S Chaurasiya","year":"2020","unstructured":"Chaurasiya, S. et al. Oncolytic poxvirus CF33-hNIS-DeltaF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. Oncoimmunology 9, 1729300 (2020).","journal-title":"Oncoimmunology"},{"key":"8717_CR31","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/mt.2016.66","volume":"24","author":"AM Noonan","year":"2016","unstructured":"Noonan, A. M. et al. Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol. Ther. 24, 1150\u20131158 (2016).","journal-title":"Mol. Ther."},{"key":"8717_CR32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/17474124.2021.1991792","volume":"15","author":"P Konyn","year":"2021","unstructured":"Konyn, P., Ahmed, A. & Kim, D. Current epidemiology in hepatocellular carcinoma. Expert Rev. Gastroenterol. Hepatol. 15, 1295\u20131307 (2021).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"8717_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn, K. A., Petrick, J. L. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma. Hepatology 73, 4\u201313 (2021).","journal-title":"Hepatology"},{"key":"8717_CR34","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/med.21281","volume":"33","author":"E De Clercq","year":"2013","unstructured":"De Clercq, E. A cutting-edge view on the current state of antiviral drug development. Med. Res. Rev. 33, 1249\u20131277 (2013).","journal-title":"Med. Res. Rev."},{"key":"8717_CR35","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/1535-7163.MCT-21-0851","volume":"21","author":"WR Wiedemeyer","year":"2022","unstructured":"Wiedemeyer, W. R. et al. ABBV-011, a novel, calicheamicin-based antibody\u2013drug conjugate, targets SEZ6 to eradicate small cell lung cancer tumors. Mol. Cancer Ther. 21, 986\u2013998 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"8717_CR36","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3892\/mmr.2021.12473","volume":"24","author":"X Wang","year":"2021","unstructured":"Wang, X., Yang, B., Li, Y., Luo, J. & Wang, Y. AKR1C1 alleviates LPS-induced ALI in mice by activating the JAK2\/STAT3 signaling pathway. Mol. Med. Rep. 24, 833 (2021); retraction 31, 84 (2025).","journal-title":"Mol. Med. Rep."},{"key":"8717_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/00071668.2020.1812524","volume":"62","author":"A Truong","year":"2020","unstructured":"Truong, A. et al. Molecular identification and characterisation of a novel chicken leukocyte immunoglobulin-like receptor A5. Br. Poult. Sci. 62, 68\u201380 (2020).","journal-title":"Br. Poult. Sci."},{"key":"8717_CR38","doi-asserted-by":"publisher","first-page":"109746","DOI":"10.1016\/j.cbi.2021.109746","volume":"351","author":"X Chu","year":"2021","unstructured":"Chu, X. et al. Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors. Chem. Biol. Interact. 351, 109746 (2021).","journal-title":"Chem. Biol. Interact."},{"key":"8717_CR39","doi-asserted-by":"publisher","first-page":"e2245836","DOI":"10.1001\/jamanetworkopen.2022.45836","volume":"5","author":"Z-X Liu","year":"2022","unstructured":"Liu, Z.-X. et al. Whole-exome sequencing among Chinese patients with hereditary diffuse gastric cancer. JAMA Netw. Open 5, e2245836 (2022).","journal-title":"JAMA Netw. Open"},{"key":"8717_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12943-022-01529-5","volume":"21","author":"W Liu","year":"2022","unstructured":"Liu, W. et al. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma. Mol. Cancer 21, 72 (2022).","journal-title":"Mol. Cancer"},{"key":"8717_CR41","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/1878-0261.13135","volume":"16","author":"A Scheiter","year":"2022","unstructured":"Scheiter, A. et al. RASSF1A independence and early galectin\u20101 upregulation in PIK3CA\u2010induced hepatocarcinogenesis: new therapeutic venues. Mol. Oncol. 16, 1091\u20131118 (2022).","journal-title":"Mol. Oncol."},{"key":"8717_CR42","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"8717_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"8717_CR44","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/gb-2011-12-3-r22","volume":"12","author":"A Roberts","year":"2011","unstructured":"Roberts, A., Trapnell, C., Donaghey, J., Rinn, J. L. & Pachter, L. Improving RNA-seq expression estimates by correcting for fragment bias. Genome Biol. 12, R22 (2011).","journal-title":"Genome Biol."},{"key":"8717_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511\u2013515 (2010).","journal-title":"Nat. Biotechnol."},{"key":"8717_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"8717_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"8717_CR48","doi-asserted-by":"publisher","first-page":"W345","DOI":"10.1093\/nar\/gkm391","volume":"35","author":"L Kong","year":"2007","unstructured":"Kong, L. et al. CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res. 35, W345\u2013W349 (2007).","journal-title":"Nucleic Acids Res."},{"key":"8717_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/1471-2105-15-311","volume":"15","author":"A Li","year":"2014","unstructured":"Li, A., Zhang, J. & Zhou, Z. PLEK: a tool for predicting long non-coding RNAs and messenger RNAs based on an improved k-mer scheme. BMC Bioinformatics 15, 311 (2014).","journal-title":"BMC Bioinformatics"},{"key":"8717_CR50","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1093\/nar\/gkt646","volume":"41","author":"L Sun","year":"2013","unstructured":"Sun, L. et al. Utilizing sequence intrinsic composition to classify protein-coding and long non-coding transcripts. Nucleic Acids Res. 41, e166 (2013).","journal-title":"Nucleic Acids Res."},{"key":"8717_CR51","doi-asserted-by":"publisher","first-page":"D222","DOI":"10.1093\/nar\/gkt1223","volume":"42","author":"RD Finn","year":"2014","unstructured":"Finn, R. D. et al. Pfam: the protein families database. Nucleic Acids Res. 42, D222\u2013D230 (2014).","journal-title":"Nucleic Acids Res."},{"key":"8717_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13059-014-0571-3","volume":"16","author":"Y Gao","year":"2015","unstructured":"Gao, Y., Wang, J. & Zhao, F. CIRI: an efficient and unbiased algorithm for de novo circular RNA identification. Genome Biol. 16, 4 (2015).","journal-title":"Genome Biol."},{"key":"8717_CR53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cell.2014.09.001","volume":"159","author":"XO Zhang","year":"2014","unstructured":"Zhang, X. O. et al. Complementary sequence-mediated exon circularization. Cell 159, 134\u2013147 (2014).","journal-title":"Cell"},{"key":"8717_CR54","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"},{"key":"8717_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e324 (2019).","journal-title":"Cell Syst."},{"key":"8717_CR56","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"8717_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"8717_CR58","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11626-007-9060-2","volume":"43","author":"JK Cooper","year":"2007","unstructured":"Cooper, J. K. et al. Species identification in cell culture: a two-pronged molecular approach. In Vitro Cell Dev. Biol. Anim. 43, 344\u2013351 (2007).","journal-title":"In Vitro Cell Dev. Biol. Anim."}],"updated-by":[{"DOI":"10.1038\/s41586-025-09022-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08717-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08717-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08717-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:03:56Z","timestamp":1746605036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08717-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":58,"journal-issue":{"issue":"8062","published-print":{"date-parts":[[2025,5,8]]}},"alternative-id":["8717"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-08717-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4608261\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-025-09022-x","URL":"https:\/\/doi.org\/10.1038\/s41586-025-09022-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CNBG-Virogin Biotech (Shanghai) owns the patent rights for VG161 in mainland China. Virogin Biotech owns the patent rights for VG161 outside mainland China. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}